[1]
|
Neuwelt, E., et al. (2008) Strategies to Advance Translational Research into Brain Barriers. The Lancet Neurology, 7, 84-96. https://doi.org/10.1016/S1474-4422(07)70326-5
|
[2]
|
Arvanitis, C.D., Ferraro, G.B. and Jain, R.K. (2019) The Blood-Brain Barrier and Blood-Tumour Barrier in Brain Tumours and Metastases. Nature Reviews. Cancer, 20, 26-41. https://doi.org/10.1038/s41568-019-0205-x
|
[3]
|
Lee, G., et al. (2001) Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations. Pharmacological Reviews, 53, 569-596. https://doi.org/10.1146/annurev.pharmtox.41.1.569
|
[4]
|
Ouyang, Q., et al. (2021) New Advances in Brain-Targeting Nano-Drug Delivery Systems for Alzheimer’s Disease. Journal of Drug Targeting, 30, 61-81. https://doi.org/10.1080/1061186X.2021.1927055
|
[5]
|
Siti, Y. (2010) Structure and Function of the Blood-Brain Barrier. Frontiers in Pharmacology, 11, Article No. 914.
https://doi.org/10.3389/conf.fphar.2010.02.00002
|
[6]
|
Daniels, T.R., et al. (2012) The Transferrin Receptor and the Targeted Delivery of Therapeutic Agents against Cancer. Biochimica et Biophysica Acta BBA—General Subjects, 1820, 291-317. https://doi.org/10.1016/j.bbagen.2011.07.016
|
[7]
|
Sharma, G., et al. (2019) Advances in Nanocarriers Enabled Brain Targeted Drug Delivery across Blood Brain Barrier. International Journal of Pharmaceutics, 559, 360-372. https://doi.org/10.1016/j.ijpharm.2019.01.056
|
[8]
|
Poduslo, J.F., Curran, G.L. and Berg, C.T. (1994) Macromolecular Permeability across the Blood-Nerve and Blood-Brain Barriers. Proceedings of the National Academy of Sciences, 91, 5705-5709.
https://doi.org/10.1073/pnas.91.12.5705
|
[9]
|
Yu, Y.J. and Watts, R.J. (2013) Developing Therapeutic Antibodies for Neurodegenerative Disease. Neurotherapeutics, 10, 459-472. https://doi.org/10.1007/s13311-013-0187-4
|
[10]
|
Sevigny, J., et al. (2016) The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease. Nature, 537, 50-56.
https://doi.org/10.1038/nature19323
|
[11]
|
Chen, R.J., Zhao, X. and Hu, K.L. (2019) Physically Open BBB. In: Gao, H.L. and Gao, X.L., Eds., Brain Targeted Drug Delivery System: A Focus on Nanotechnology and Nanoparticulates, Elsevier, Amsterdam, 197-217.
https://doi.org/10.1016/B978-0-12-814001-7.00009-3
|
[12]
|
Frster, C. (2008) Tight Junctions and the Modulation of Barrier Function in Disease. Histochemistry and Cell Biology, 130, 55-70. https://doi.org/10.1007/s00418-008-0424-9
|
[13]
|
Li, G., Shao, K. and Umeshappa, C.S. (2019) Recent Progress in Blood-Brain Barrier Transportation Research. In: Gao, H.L. and Gao, X.L., Eds., Brain Targeted Drug Delivery System: A Focus on Nanotechnology and Nanoparticulates, Elsevier, Amsterdam, 33-51. https://doi.org/10.1016/B978-0-12-814001-7.00003-2
|
[14]
|
O’Kane, R.L., et al. (2006) Cationic Amino Acid Transport across the Blood-Brain Barrier Is Mediated Exclusively by System Y+. AJP Endocrinology & Metabolism, 291, E412-E419. https://doi.org/10.1152/ajpendo.00007.2006
|
[15]
|
Li, R.X., He, Y.W., et al. (2018) Cell Mem-brane-Based Nanoparticles: A New Biomimetic Platform for Tumor Diagnosis and Treatment. Acta Pharmaceutica Sini-ca B, 8, 14-22. https://doi.org/10.1016/j.apsb.2017.11.009
|
[16]
|
Willingham, M.C. and Pastan, I. (1980) The Re-ceptosome: An Intermediate Organelle of Receptor-Mediated Endocytosis in Cultured Fibroblasts. Cell, 21, 67-77. https://doi.org/10.1016/0092-8674(80)90115-4
|
[17]
|
Gao, H. (2019) Introduction and Overview. In: Gao, H.L. and Gao, X.L., Eds., Brain Targeted Drug Delivery System, Elsevier, Amsterdam, 1-4. https://doi.org/10.1016/B978-0-12-814001-7.00001-9
|
[18]
|
Kbj, A., et al. (2019) Targeting the Transferrin Receptor for Brain Drug Delivery. Progress in Neurobiology, 181, Article ID: 101665. https://doi.org/10.1016/j.pneurobio.2019.101665
|
[19]
|
Aisen, P., Leibman, A. and Zweier, J. (1978) Stoichiometric and Site Characteristics of the Binding of Iron to Human Transferrin. Journal of Biological Chemistry, 253, 1930-1937. https://doi.org/10.1016/S0021-9258(19)62337-9
|
[20]
|
Kleven, M.D., Jue, S. and Enns, C.A. (2018) Transferrin Receptors TfR1 and TfR2 Bind Transferrin through Differing Mechanisms. Biochemistry, 57, 1552-1559. https://doi.org/10.1021/acs.biochem.8b00006
|
[21]
|
Robb, A. and Wessling-Resnick, M. (2004) Regulation of Transferrin Receptor 2 Protein Levels by Transferrin. Blood, 104, 4294-4299. https://doi.org/10.1182/blood-2004-06-2481
|
[22]
|
Feder, J.N., et al. (1998) The Hemochromatosis Gene Product Complexes with the Transferrin Receptor and Lowers Its Affinity for Ligand Binding. Proceedings of the National Academy of Sciences of the United States of America, 95, 1472-1477. https://doi.org/10.1073/pnas.95.4.1472
|
[23]
|
Klausner, R.D., et al. (1983) Binding of Apotransferrin to K562 Cells: Explanation of the Transferrin Cycle. Proceedings of the National Academy of Sciences, 80, 2263-2266. https://doi.org/10.1073/pnas.80.8.2263
|
[24]
|
Zhou, X., Smith, Q.R. and Liu, X. (2021) Brain Penetrating Peptides and Peptide-Drug Conjugates to Overcome the Blood-Brain Barrier and Target CNS Diseases. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 13, e1695. https://doi.org/10.1002/wnan.1695
|
[25]
|
Allden, S.J., et al. (2019) The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idio-pathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 200, 209-219.
https://doi.org/10.1164/rccm.201809-1775OC
|
[26]
|
Farrington, G.K., et al. (2014) A Novel Platform for Engineer-ing Blood-Brain Barrier-Crossing Bispecific Biologics. FASEB Journal, 28, 4764-4778.
|
[27]
|
Crawford, L., Rosch, J. and Putnam, D. (2016) Concepts, Technologies, and Practices for Drug Delivery past the Blood-Brain Barrier to the Central Nervous System. Journal of Controlled Release, 240, 251-266.
https://doi.org/10.1016/j.jconrel.2015.12.041
|
[28]
|
Jca, B., et al. (2019) Alzheimer’s Disease Drug Development Pipeline: 2019. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 5, 272-293. https://doi.org/10.1016/j.trci.2019.05.008
|
[29]
|
Ward, E.S. and Ober, R.J. (2018) Targeting FcRn to Generate Anti-body-Based Therapeutics. Cancel, 39, 892-904.
https://doi.org/10.1016/j.tips.2018.07.007
|
[30]
|
Thom, G., et al. (2018) Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26. Molecular Pharmaceutics, 15, 1420-1431.
https://doi.org/10.1021/acs.molpharmaceut.7b00937
|
[31]
|
Moos, T. and Morgan, E.H. (2001) Restricted Transport of Anti-Transferrin Receptor Antibody (OX26) through the Blood-Brain Barrier in the Rat. Journal of Neurochemistry, 79, 119-129.
https://doi.org/10.1046/j.1471-4159.2001.00541.x
|
[32]
|
Paris-Robidas, S., et al. (2011) In Vivo Labeling of Brain Capillary Endothelial Cells after Intravenous Injection of Monoclonal Antibodies Targeting the Transferrin Receptor. Molecular Pharmacology, 80, 32-39.
https://doi.org/10.1124/mol.111.071027
|
[33]
|
Yu, Y.J., et al. (2011) Boosting Brain Uptake of a Therapeutic Anti-body by Reducing Its Affinity for a Transcytosis Target. Science Translational Medicine, 3, 84ra44. https://doi.org/10.1126/scitranslmed.3002230
|
[34]
|
Hanzatian, D.K., et al. (2015) Blood-Brain Barrier (BBB) Pene-trating Dual Specific Binding Proteins for Treating Brain and Neurological Diseases.
|
[35]
|
Burrell, et al. (2017) En-hanced Delivery of IL-1 Receptor Antagonist to the Central Nervous System as a Novel Anti-Transferrin Recep-tor-IL-1RA Fusion Reverses Neuropathic Mechanical Hypersensitivity. Pain, 158, 660-668.
https://doi.org/10.1097/j.pain.0000000000000810
|
[36]
|
Do, T.M., et al. (2020) Tetravalent Bispecific Tandem An-tibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model. Molecular Therapy: Methods & Clinical Development, 19, 58-77.
https://doi.org/10.1016/j.omtm.2020.08.014
|
[37]
|
Niewoehner, J., et al. (2014) Increased Brain Penetration and Po-tency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. Neuron, 81, 49-60. https://doi.org/10.1016/j.neuron.2013.10.061
|
[38]
|
Greta, H., et al. (2017) Bivalent Brain Shuttle Increases Anti-body Uptake by Monovalent Binding to the Transferrin Receptor. Theranostics, 7, 308-318. https://doi.org/10.7150/thno.17155
|
[39]
|
Bien-Ly, N., et al. (2014) Transferrin Receptor (TfR) Trafficking Deter-mines Brain Uptake of TfR Antibody Affinity Variants. Journal of Experimental Medicine, 211, 233-244. https://doi.org/10.1084/jem.20131660
|
[40]
|
Villaseor, R., et al. (2016) Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier. Scientific Reports, 6, Article No. 25658. https://doi.org/10.1038/srep25658
|
[41]
|
Huotari, J. and Helenius, A. (2014) Endosome Maturation. EMBO Journal, 30, 3481-3500.
https://doi.org/10.1038/emboj.2011.286
|
[42]
|
Lao, B.J. and Kamei, D.T. (2010) Improving Therapeutic Properties of Protein Drugs through Alteration of Intracellular Trafficking Pathways. Biotechnology Progress, 24, 2-7. https://doi.org/10.1021/bp070080b
|
[43]
|
Sade, H., et al. (2014) A Human Blood-Brain Barrier Transcytosis Assay Reveals Antibody Transcytosis Influenced by pH-Dependent Receptor Binding. PLoS ONE, 9, e96340. https://doi.org/10.1371/journal.pone.0096340
|
[44]
|
Tillotson, B.J., et al. (2015) Engineering an Anti-Transferrin Receptor ScFv for pH-Sensitive Binding Leads to Increased Intracellular Accumulation. PLoS ONE, 10, e0145820. https://doi.org/10.1371/journal.pone.0145820
|
[45]
|
Roberto, et al. (2017) Sorting Tubules Regulate Blood-Brain Barrier Transcytosis. Cell Reports, 21, 3256-3270.
https://doi.org/10.1016/j.celrep.2017.11.055
|
[46]
|
Zuchero, Y.J.Y., et al. (2016) Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies. Neuron, 89, 70-82. https://doi.org/10.1016/j.neuron.2015.11.024
|
[47]
|
Lee, H.J., et al. (2000) Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse. Journal of Pharmacology and Experimental Therapeutics, 292, 1048-1052.
|
[48]
|
Boado, R.J., et al. (2007) Fusion Antibody for Alzheimer’s Disease with Bi-Directional Transport across the Blood-Brain Barrier and Abeta Fibril Disaggregation. Bioconjugate Chemistry, 18, 447-455.
https://doi.org/10.1021/bc060349x
|
[49]
|
Chang, R., et al. (2017) Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer’s Disease. Molecular Pharmaceutics, 14, 2340-2349. https://doi.org/10.1021/acs.molpharmaceut.7b00200
|
[50]
|
Sonoda, H., et al. (2018) A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Muco-polysaccharidosis II. Molecular Therapy, 26, 1366-1374.
https://doi.org/10.1016/j.ymthe.2018.02.032
|
[51]
|
Zhou, Q.H., et al. (2010) Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse. Drug Metabolism & Disposition the Biological Fate of Chemicals, 38, 566.
https://doi.org/10.1124/dmd.109.031534
|
[52]
|
Kariolis, M.S., et al. (2020) Brain Delivery of Therapeutic Proteins Using an Fc Fragment Blood-Brain Barrier Transport Vehicle in Mice and Monkeys. Science Translational Medicine, 12, eaay1359.
https://doi.org/10.1126/scitranslmed.aay1359
|
[53]
|
Stina, S., et al. (2018) Efficient Clearance of Aβ Protofibrils in AβPP-Transgenic Mice Treated with a Brain-Penetrating Bifunctional Antibody. Alzheimer’s Research & Therapy, 10, 49.
https://doi.org/10.1186/s13195-018-0377-8
|
[54]
|
Rao, E., et al. (2009) Antibodies That Bind IL-4 and/or IL-13 and Their Uses.
|
[55]
|
Meister, S.W., et al. (2020) An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor. International Journal of Molecular Sciences, 21, 2999. https://doi.org/10.3390/ijms21082999
|
[56]
|
Sehlin, D., et al. (2020) Brain Delivery of Biologics Using a Cross-Species Reactive Transferrin Receptor 1 VNAR Shuttle. The FASEB Journal, 34, 13272-13283.
|
[57]
|
Yang, J., et al. (2020) Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice. Molecular Pharmaceutics, 17, 2831-2839.
https://doi.org/10.1021/acs.molpharmaceut.0c00231
|
[58]
|
Pizzo, M.E., et al. (2017) Intrathecal Antibody Distribu-tion in the Rat Brain: Surface Diffusion, Perivascular Transport and Osmotic Enhancement of Delivery. Journal of Physi-ology, 596, 445-475. https://doi.org/10.1113/JP275105
|
[59]
|
Faresj, R., et al. (2021) Brain Pharmacokinetics of Two BBB Penetrating Bispecific Antibodies of Different Size. Fluids and Barriers of the CNS, 18, Article No. 26. https://doi.org/10.1186/s12987-021-00257-0
|
[60]
|
Abbott, N.J. (2004) Evidence of Bulk Flow of Brain Interstitial Fluid: Significance for Physiology and Pathology. Neurochemistry International, 45, 545-552. https://doi.org/10.1016/j.neuint.2003.11.006
|
[61]
|
Yun, Z. and Pardridge, W.M. (2001) Mediated Efflux of IgG Molecules from Brain to Blood across the Blood-Brain Barrier. Journal of Neuroimmunology, 114, 168-172. https://doi.org/10.1016/S0165-5728(01)00242-9
|
[62]
|
Sezgin-Bayindir, Z., et al. (2016) Evaluation of Various Block Copolymers for Micelle Formation and Brain Drug Delivery: In Vitro Characterization and Cellular Uptake Studies. Journal of Drug Delivery Science and Technology, 36, 120-129. https://doi.org/10.1016/j.jddst.2016.10.003
|
[63]
|
Pardridge, W.M. (2020) Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain. Frontiers in Medical Technology, 2, Article ID: 602236. https://doi.org/10.3389/fmedt.2020.602236
|
[64]
|
Pardridge, W.M. (2010) Preparation of Trojan Horse Liposomes (THLs) for Gene Transfer across the Blood-Brain Barrier. Cold Spring Harbor Protocols, 2010, pdb.prot5407. https://doi.org/10.1101/pdb.prot5407
|
[65]
|
Jiang, D., Lee, H. and Pardridge, W.M. (2020) Plasmid DNA Gene Therapy of the Niemann-Pick C1 Mouse with Transferrin Receptor-Targeted Trojan Horse Liposomes. Scientific Reports, 10, Article No. 13334.
|
[66]
|
Kang, S., et al. (2020) Muscone/RI7217 Co-Modified Upward Messenger DTX Liposomes Enhanced Permeability of Blood-Brain Barrier and Targeting Glioma. Theranostics, 10, 4308-4322. https://doi.org/10.7150/thno.41322
|
[67]
|
Wu, Y., et al. (2019) Brain Targeting of Baicalin and Salvianolic Acid B Combination by OX26 Functionalized Nanostructured Lipid Carriers. International Journal of Pharmaceutics, 571, Arti-cle ID: 118754.
https://doi.org/10.1016/j.ijpharm.2019.118754
|
[68]
|
Johnsen, K.B., et al. (2019) Modulating the Antibody Density Changes the Uptake and Transport at the Blood-Brain Barrier of Both Transferrin Receptor-Targeted Gold Nanoparticles and Liposomal Cargo. Journal of Controlled Release, 295, 237-249. https://doi.org/10.1016/j.jconrel.2019.01.005
|
[69]
|
Couch, J.A., et al. (2013) Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier. Science Translational Medicine, 5, 183ra57. https://doi.org/10.1126/scitranslmed.3005338
|
[70]
|
Sun, J., et al. (2019) Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice. Molecular Pharmaceutics, 16, 3534-3543.
https://doi.org/10.1021/acs.molpharmaceut.9b00369
|
[71]
|
Lo, M., et al. (2017) Effector-Attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. Journal of Biological Chemistry, 292, 3900-3908. https://doi.org/10.1074/jbc.M116.767749
|
[72]
|
Yu, Y.J., et al. (2014) Therapeutic Bispecific Antibodies Cross the Blood-Brain Barrier in Nonhuman Primates. Science Translational Medicine, 6, 261ra154. https://doi.org/10.1126/scitranslmed.3009835
|
[73]
|
Ruano-Salguero, J.S. and Lee, K.H. (2020) Antibody Transcytosis across Brain Endothelial-Like Cells Occurs Nonspecifically and Independent of FcRn. Scientific Reports, 10, Article No. 3685.
https://doi.org/10.1038/s41598-020-60438-z
|